United Therapeutics Corp Stock Forecast for 2023 - 2025 - 2030

Updated on 11/28/2023

Stock Rating
12
Price Target
$300.00
Consensus
Outperform
Upside
30.21%
Analysts
4
Stock Rating
12
Upside
30.21%
Analysts
4
Price Target
$300.00

United Therapeutics Corp Stock Forecast and Price Target

United Therapeutics Corp's stock is projected to advance by 30.21% from the previous closing price if it reaches the average target of $300.00 by the year's end, as four reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $375.00 and a low-end estimate of $177.00. If you're looking for information on United Therapeutics Corp stock, consider checking out the forecasts for comparable firms such as NasdaqGS:REGN.

$300.00

30.21% Upside

Outperform
Outperform

United Therapeutics Corp Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, United Therapeutics Corp's Price has grown, moving from $142.47 to $183.98 – an increase of 29.13%. In the next year, analysts predict that Fair Value will jump to $224.38 – up 21.96% from the current level. Looking ahead to eight years, experts forecast that Fair Value will grow by 20.23%.

2023 Fair Value Forecast
$224.38
2024 Fair Value Forecast
$237.71
2025 Fair Value Forecast
$267.65
2026 Fair Value Forecast
$273.05
2027 Fair Value Forecast
$252.68
2028 Fair Value Forecast
$227.03
2029 Fair Value Forecast
$219.21
2030 Fair Value Forecast
$221.19
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 16
$591.60 Buy/Sell $594.01 9.87%
JNJ Stock Forecast Johnson & Johnson Outperform 10
$151.63 Buy/Sell $176.14 13.43%
MRK Stock Forecast Merck Outperform 5
$100.18 Buy/Sell $123.75 24.78%
PFE Stock Forecast Pfizer Inc Outperform 3
$29.69 Buy/Sell $40.55 26.31%
BMY Stock Forecast Bristol-Myers Squibb Co Outperform 2
$48.92 Buy/Sell $64.26 25.72%

United Therapeutics Corp Revenue Forecast for 2023 - 2025 - 2030

In the last three years, United Therapeutics Corp's Revenue has grown, moving from $1.45B to $1.94B – an increase of 33.65%. In the next year, analysts predict that Revenue will jump to $2.25B – up 16.12% from the current level. Looking ahead to eight years, experts forecast that Revenue will grow by 117.71%.

2023 Rev Forecast
$2.25B
2024 Rev Forecast
$2.50B
2025 Rev Forecast
$2.81B
2026 Rev Forecast
$3.14B
2027 Rev Forecast
$3.41B
2028 Rev Forecast
$3.47B
2029 Rev Forecast
$3.78B
2030 Rev Forecast
$4.22B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
VRTX Stock Forecast Vertex Pharmaceuticals Inc Outperform 15
$347.04 Buy/Sell $395.90 12.38%
REGN Stock Forecast Regeneron Pharmaceuticals Inc Outperform 2
$801.14 Buy/Sell $796.73 14.09%
ZTS Stock Forecast Zoetis Inc Outperform 18
$176.97 Buy/Sell $217.57 18.66%

United Therapeutics Corp Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ALNY Stock Forecast Alnylam Pharmaceuticals Inc Outperform 7
$161.36 Buy/Sell $245.24 42.54%
BAX Stock Forecast Baxter International Inc Outperform 17
$36.34 Buy/Sell $45.50 22.45%
VTRS Stock Forecast Viatris Inc Hold 8
$9.14 Buy/Sell $11.74 25.82%

United Therapeutics Corp Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Free Cash Flow for United Therapeutics Corp has grown by 328.63%, going from $-290.30M to $663.70M. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $937.00M – an increase of 41.18%. Over the next eight years, experts anticipate that Free Cash Flow growth for United Therapeutics Corp will be 88.54%.

2023 FCF Forecast
$0.94B
2024 FCF Forecast
$1.09B
2025 FCF Forecast
$1.23B
2026 FCF Forecast
$1.32B
2027 FCF Forecast
$1.31B
2028 FCF Forecast
$1.26B
2029 FCF Forecast
$1.25B
2030 FCF Forecast
$1.25B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IONS Stock Forecast Ionis Pharmaceuticals Inc Outperform 9
$48.34 Buy/Sell $51.20 24.12%
CTLT Stock Forecast Catalent Outperform 15
$39.46 Buy/Sell $49.29 21.64%
PRGO Stock Forecast Perrigo Co PLC Outperform 16
$30.46 Buy/Sell $45.67 44.45%

United Therapeutics Corp Net Income Forecast for 2023 - 2025 - 2030

United Therapeutics Corp's Net Income has seen growth In the last three years, going from $-104.50M to $727.30M – a gain of 795.98% In the next year, analysts believe that Net Income will reach $1.00B – an increase of 38.14%. For the next eight years, the forecast is forNet Income to grow by 21.68%.

2023 NI Forecast
$1.00B
2024 NI Forecast
$1.08B
2025 NI Forecast
$1.18B
2026 NI Forecast
$1.18B
2027 NI Forecast
$1.07B
2028 NI Forecast
$0.94B
2029 NI Forecast
$0.89B
2030 NI Forecast
$0.89B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BCPC Stock Forecast Balchem Outperform 18
$122.71 Buy/Sell $145.00 22.24%
MDGL Stock Forecast Madrigal Pharmaceuticals Outperform 4
$190.94 Buy/Sell $170.08 73.09%
NEOG Stock Forecast Neogen Outperform 16
$16.60 Buy/Sell $37.00 34.04%

United Therapeutics Corp EBITDA Forecast for 2023 - 2025 - 2030

United Therapeutics Corp's EBITDA has grown in the last three years, jumping from $-131.70M to $1.04B – an increase of 889.90%. In the next year, analysts predict that EBITDA will reach $1.27B – an increase of 21.82%. For the next eight years, the forecast is for EBITDA to grow by 4.59%.

2023 EBITDA Forecast
$1.27B
2024 EBITDA Forecast
$1.23B
2025 EBITDA Forecast
$1.47B
2026 EBITDA Forecast
$1.48B
2027 EBITDA Forecast
$1.34B
2028 EBITDA Forecast
$1.18B
2029 EBITDA Forecast
$1.11B
2030 EBITDA Forecast
$1.09B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CYTK Stock Forecast Cytokinetics Inc Outperform 10
$31.22 Buy/Sell $61.75 92.18%
AMPH Stock Forecast Amphastar Pharmaceuticals Outperform 14
$54.41 Buy/Sell $69.00 21.30%
CORT Stock Forecast Corcept Therapeutics Outperform 16
$25.45 Buy/Sell $0.00 41.45%

United Therapeutics Corp EBIT Forecast for 2023 - 2025 - 2030

In the last three years, United Therapeutics Corp's EBIT has increased by 656.87%, going from $-177.60M to $989.00M. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $1.18B – an increase of 19.14%. The United Therapeutics Corp forecast is for EBIT to reach $2.44B or grow by 147.12%.

2023 EBIT Forecast
$1.18B
2024 EBIT Forecast
$1.29B
2025 EBIT Forecast
$1.53B
2026 EBIT Forecast
$1.74B
2027 EBIT Forecast
$1.89B
2028 EBIT Forecast
$1.93B
2029 EBIT Forecast
$2.14B
2030 EBIT Forecast
$2.44B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
INDV Stock Forecast Indivior PLC Buy 14
£12.38 Buy/Sell £3.79 134.25%
TGTX Stock Forecast TG Therapeutics Outperform 9
$12.63 Buy/Sell $26.83 90.02%
CPRX Stock Forecast Catalyst Pharmaceuticals Outperform 16
$14.21 Buy/Sell $23.30 75.93%

United Therapeutics Corp EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, United Therapeutics Corp's EPS has grown, moving from $12.94 to $16.71 – an increase of 29.13%. In the next year, analysts predict that EPS will jump to $20.38 – up 21.96% from the current level. Looking ahead to eight years, experts forecast that EPS will grow by 20.23%.

2023 EPS Forecast
$20.38
2024 EPS Forecast
$21.59
2025 EPS Forecast
$24.31
2026 EPS Forecast
$24.80
2027 EPS Forecast
$22.95
2028 EPS Forecast
$20.62
2029 EPS Forecast
$19.91
2030 EPS Forecast
$20.09
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
IRWD Stock Forecast Ironwood Pharmaceuticals Outperform 14
$9.68 Buy/Sell $17.40 106.61%
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$26.97 Buy/Sell $41.00 53.87%
ARPO Stock Forecast Aerpio Pharmaceuticals - 6
$30.30 Buy/Sell $0.00 -100.00%